Is It Possible to Reduce the Risk of Cardiovascular Events in Subjects Suffering from Intermittent Claudication of the Lower Limbs?

Summary

This study meta-analysed randomized, double-blind, placebo controlled trials in patients with intermittent claudication of the lower limbs comparing ticlopidine to placebo in order to test the hypothesis that the drug, a pure antiplatelet agent, is able to reduce the incidence of thrombotic cardio-vascular events on atherosclerotic arteries in these patients. A highly significant reduction, from 9% to 3% (p ranging from 0.006 to 0.002), was observed for fatal or non-fatal cardio-vascular events in a total of 611 patients (301 with ticlopidine, 310 with placebo). The duration of follow-up ranged from 6 to 12 months. Side-effects, defined as withdrawal from study medication for any reason but death, cardio-vascular events or cancer, were 2.4 times more frequent in the ticlopidine treated patients as compared to placebo. We concluded that in this high risk population, prevention of cardio-vascular events is likely to be effective.

Keywords

Meta-analysis - Intermittent claudication - Antiplatelet agent - Cardiovascular risks

• References

• 1 Imparato AM, Kim GE, Davidson T, Crowley JG. Intermittent claudication: its natural course. J Cardiovasc Dis 1976; 34: 455-462
• 2 Juergens JL, Barker NW, Hines EA. Arteriosclerosis obliterans: review of 520 cases with special reference to pathogenic and prognostic factors. Circulation 1960; 21: 188-195
• 3 Kallero KS. Mortality and morbidity in patients with intermittent claudication as defined by venous occlusion plethysmography. A ten-year follow up study. J Chron Dis 1981; 34: 455-462
• 4 Kannel WB, Shurtleff D. The natural history of arteriosclerosis obliterans. Cardiovasc Clin 1971; 3: 37-52
• 5 Blombery PA. Intermittent claudication: an update on management. Drugs 1987; 34: 404-410
• 6 Jelnes R, Gaardsting O, Hougaard Jensen K, Baekgaard N, Tonnesen KH, Schroeder T. Fate in intermittent claudication: outcome and risk factors. Br Med J 1986; 293: 1137-1140
• 7 Saltiel E, Ward A. Ticlopidine, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in platelet-dependent disease states. Drugs 1987; 34: 222-262
• 8 Arcan JC, Blanchard J, Boissel JP, Destors JM, Panak E. on behalf of the ACT Research Group. Multicenter Double-blind Study of Ticlopidine in the Treatment of Intermittent Claudication and the Prevention of its Complications. Angiology 1988; 39: 802-811
• 9 Sacks HS, Berrier J, Reitman D, Ancona-Berk VA, Chalmers TC. Meta-analyses of randomized trials. N Engl J Med 1987; 316: 450-455
• 10 Boissel JP, Blanchard J, Furberg C, Panak E, Peyrieux JC, Sacks H. On behalf of the Meta-analysis Cooperative Group. Considerations for the meta-analysis of randomized clinical trials: summary of a panel discussion. Controlled Clinical Trials. in press.
• 11 Ellis DJ. Treatment of intermittent claudication with ticlopidine. Abstract addendum. Presented at the International Committee on Thrombosis and Haemostasis 32nd Annual Meeting and the Mediterranean League Against Thromboembolic Diseases. 9th Congress Jerusalem: 1–6 June 1986
• 12 Cloarec M, Caillard PH, Mouren X. Double-blind clinical trial of ticlopidine versus placebo in peripheral atherosclerotic disease of the legs. Thromb Res 1986; suppl (Suppl. 06) 160
• 13 Stiegler H, Hess H, Mietaschk A, Trampisch HJ, Ingrisch H. EinfluB von Ticlopidin auf die periphere obliterierende Arteriopathie. Dtsch Med Wochenschr 1984; 109: 1240-1243
• 14 Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1955; 22: 719-748
• 15 Fleiss JL. Statistical Methods for Rates and Proportions. Wiley; New York: 1973
• 16 Cochran WG. Some methods of strengthening the common X2 tests. Biometrics 1954; 10: 417-451
• 17 DerSimonian R, Laird NM. Meta-analysis in clinical trials. Controlled Clinical Trials 1986; 7: 177-188
• 18 Bulpitt CJ. Confidence intervals. Lancet 1987; i: 494-497
• 19 Baptista J, Pike MC. Exact two-sided confidence limits for the odds ratio in a 2 × 2 table. Algorithm AS115. Appl Stat 1977; 26: 214-220
• 20 Stuart J, Aukland A, George AJ, Hurlow RA. Effect of platelet inhibition with ticlopidine on fibrinolytic activity in patients with atherosclerosis. Haemostasis July 1982; (suppl.): abstract 179
• 21 Drouin P, Stoltz JF, Pointel JP, Verry M, Gaillard S, Voisin P, Debry G. Rheological and platelet abnormalities in diabetic peripheral arterial diseases. Their correction by an antiaggregating agent: ticlopidine. 12th World Congr Angiology. Athens: 1980. abstract 654
• 22 Klingemann HG, Egbring R, Havemann K. Effects of ticlopidine on beta-thromboglobulin and platelet-factor-4 levels in peripheral vascular disease. Abstracts 2nd European Conference on Clinical Haemorheology 1981; 190: 95